Potential Role of Sirtuins As Epigenetic Biomarkers of the Patient with Atherosclerosis or Calcific Aortic Stenosis

ConditionAtherosclerosis and Calcific Aortic Stenosis with and Without Diabetes

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorIRCCS SYNLAB SDN

About this trial

The project aims to shed light on the role of Sirtuins, enzymes belonging to the third class of histone deacetylases (class III) involved in epigenetic modifications (deacetylation), focusing mainly on Sirtuin 6 (SIRT6), as a regulator of atherosclerosis and severe aortic valve stenosis through molecular-based and epigenetic studies in human VSMC cells.

Eligibility criteria

Qualifiers

Patients with atherosclerosis or calcific aortic stenosis with and without diabetes older than 18 years of either sex;

Patients without atherosclerosis undergoing surgical procedure for endocarditis;

Patients who will have signed informed consent

Disqualifiers

Patients for whom biological material cannot be recovered for study purposes;

Patients who refuse to participate in the study

Trial design

Treatments tested in this trial

lncRNA signature analyses

Treatment groups

3 Participants

are divided into 3 treatment groups

Sponsors and collaborators

IRCCS SYNLAB SDN

Lead sponsor

Federico II University

Collaborator

Source ClinicalTrials.gov